Atopic dermatitis phenotypes and the need for personalized medicine

Cabanillas, Beatriz; Brehler, Ann Christin; Novak, Natalija

doi:10.1097/aci.0000000000000376

Cited by 129 publications

(130 citation statements)

References 34 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The obtained results indicate that Il-17 and therefore the participation of T helper 17 may be especially crucial in concomitant AD with PS. However, in the group with psoriasis the Il-17 values were signi cantly lower despite evidence of the important role of Th17 in this disease (10,11). Perhaps this is due to too small a group or a mild form of the disease in the PS group.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Atopic dermatitis and psoriasis as overlapping syndromes.

Bożek

Zając

Krupka

2020

Preprint

View full text Add to dashboard Cite

Background: Concomitant atopic dermatitis (AD) and psoriasis (PS) are not common. However, both diseases are still of interest because of their comprehensive and diverse mechanism. The aim of the study was to present the clinical and immunological profile of patients with concomitant AD and PS coexist in comparison to patients with one of these diseases.Methods: In this observational study, 38 children with concomitant AD and PS with a mean age of 6.5 ± 3.2 yrs. were compared with similar 41 patients with only AD (5.3± 5.1 yrs) and with 28 with PS (6.4± 4.3 yrs). All patients underwent the dermatological examination including SCORAD and PASI questionnaire. TNF-α, IFN-γ, Il-2, Il-4, Il-5, Il-6, Il-8, Il-12, I-17, Il-18, Il-22, Il-33, TARC/CCL17 were measured by the use ELISA method and according manufacturer (ThermoFischer Scientific, US).Results: Patients with concomitant AD and PS were frequently boys or with overweight and with a proportional area distribution of skin lesions. A positive family history of atopic disease was more frequently reported by children with concomitant AD and PS, and with AD vs. PS. Significant differences were observed in the concentration of Il-17 in patients with AD and PS compared with that in AD or PS patients as follows: 9.1±3.7 pg/ml vs. 4.8±2.9 pg/ml and 5.2±3.9 pg/ml (PD vs. AD, p = 0.01; PD vs. PS, p = 0.03).Conclusion: AD and PS might coexist as overlapping disease. The role of T-helper 17 may be more meaningful than it appeared.

show abstract

Section: Discussionmentioning

confidence: 90%

“…This leads to skin in ammation. Then, during the progression of AD a role of the Thelper 1 pathway is also possible (10,11). Keratinocyte dysfunction is of major importance in the pathomechanism of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Atopic dermatitis and psoriasis as overlapping syndromes.

Bożek

Zając

Krupka

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In this regard, biomarkers may be central to future advancements in AD . With this in mind, predictive biomarkers for therapeutic responses were defined in AD patients treated with anti–IL‐22 therapy, perhaps opening the door to a predictive medicine approach in AD and beyond . In this way, the implications of disease heterogeneity on treatment responses may be attenuated as patients could ultimately receive personalized therapeutic approaches to treat their AD.…”

Section: The Era Of Biologics and Emerging Therapeutic Approachesmentioning

confidence: 99%

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

Moyle¹,

Cevikbas

Harden

et al. 2019

Experimental Dermatology

132

148

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness. AD is associated with an increased risk of skin infections and a reduced quality of life. Most AD treatment options to date were not designed to selectively target disease‐causing pathways that have been established for this indication. Topical therapies have limited efficacy in moderate‐to‐severe disease, and systemic agents such as corticosteroids and immunosuppressants present with tolerability issues. Advances in the understanding of AD pathobiology have made possible a new generation of more disease‐specific AD therapies. AD is characterized by the inappropriate activation of type 2 T helper (Th2) cells and type 2 innate lymphoid (ILC2) cells, with a predominant increase in type 2 cytokines in the skin, including interleukin (IL)‐13 and IL‐4. Both cytokines are implicated in tissue inflammation and epidermal barrier dysfunction, and monoclonal antibodies targeting each of these interleukins or their receptors are in clinical development in AD. In March 2017, dupilumab, a human anti–IL‐4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate‐to‐severe AD. The anti–IL‐13 monoclonal antibodies lebrikizumab and tralokinumab, which bind different IL‐13 epitopes with potentially different effects, are currently in advanced‐stage trials. Here, we briefly review the underlying pathobiology of AD, the scientific basis for current AD targets, and summarize current clinical studies of these agents, including new research to develop both predictive and response biomarkers to further advance AD therapy in the era of precision medicine.

show abstract

“…AD is not curable and has multiple etiologies, therefore treatments focus on symptom relief [4,6]. The treatment options are topical treatments such as emollients, corticosteroids, and calcineurin inhibitors (Pimecrolimus cream and tacrolimus ointment), and systemic therapies such as immunosuppressants, immune response modifiers, antihistamines, and antibiotics; however, such treatment methods have limitations [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Anti-Inflammatory Effects of Bee Venom on Phthalic Anhydride-Induced Atopic Dermatitis

Oh¹

2020

J Acupunct Res

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is a chronic inflammatory condition which can be studied using phthalic anhydride (PA) to induce AD. Anti-inflammatory properties of bee venom (BV) wereinvestigated to determine whether it may be a useful treatment for AD. Methods: AD was induced by applying to pical PA to 8-week-old HR-1 mice (N = 50), then treating with (0.1, 0.25, and 0.5 µg) or without topical BV. Body weight, ear thickness histology, enzymelinked immune sorbent assay (serum IgE concentrations), Western blot analysis [inducible nitric oxide synthase, cyclooxygenase-2, IκB-α, phospho-IκB-α, c-Jun N-terminal kinase (JNK), phospho-JNK, p38, phospho-p38, extra cellular signal-regulated kinase (ERK), and phospho-ERK], and the pull down assay for immunoblotting (p50), were used to measure inflammatory mediators. Results: PA + BV (0.1, 0.25, and 0.5 μg) significantly decreased ear thickness without altering body weight. IgE concentrations decreased in the PA + BV (0.5 µg)-treated groups compared with PAtreatment. Tumor necrosis factor-α, interleukin-1β, inducible nitric oxide synthase, cyclooxygenase-2, phospho-IκB-α, phospho-JNK, p38, phospho-p38, and phospho-ERK, all decreased following treatment with PA + BV compared with the PA-treatment alone. p50 was upregulated in the PA + BV-treated groups compared with the PA-treated group. Furthermore, the number of mast cells decreased in the PA + BV-treated groups compared with the PA-treated group. Epidermal thickness was significantly lower in the PA + BV-treated group compared with PA treatment alone. Conclusion: BV maybe a useful anti-inflammatory treatment for AD.

show abstract

Atopic dermatitis phenotypes and the need for personalized medicine

Cited by 129 publications

References 34 publications

Atopic dermatitis and psoriasis as overlapping syndromes.

Atopic dermatitis and psoriasis as overlapping syndromes.

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches

Anti-Inflammatory Effects of Bee Venom on Phthalic Anhydride-Induced Atopic Dermatitis

Contact Info

Product

Resources

About